摘要
目的观察单药小剂量多西紫杉醇3周疗法治疗老年非小细胞肺癌(NSCLC)的疗效及安全性。方法我院收治年龄>70岁NSCLC患者48例,给予多西紫杉酸60mg/㎡,每3周1次,两周期复查,治疗4～6个周期,观察疗效及不良反应。结果 48例患者均可评价疗效,完全缓解1例,部分缓解14例,有效率31.25%,中位疾病进展时间为4.3个月,1年生存率为43.75%(21/48)。FACT-L生存质量和KPS行为状态评分治疗后分别提高22分和11分,与治疗前比较差异有统计学意义(P<0.05)。主要不良反应包括1～2级粒细胞减少、血红蛋白减少和乏力,未发生3～4级的毒性反应。结论小剂量多西紫杉醇3周给药治疗老年NSCLC疗效确切,不良反应轻微,耐受性良好,值得在临床推广。
Objective To evaluate the efficacy and toxicity of taxotere administered three weekly to elderly patient with low-dose advanced non-small cell lung cancer （NSCLC）.Methods Forty eight patients older than 70 with advanced NSCLC received taxotere 60mg/m2 three times a week, followed by two-period countercheck, 4-6 weeks without treatment. Results One case was evaluated as CR, 14 cases as PR among 48patients, 31.25% as RR. One year survival rate was 43.75% （21/48）. Median time to progression （TTP） was 4.3 months. The scores of functional assessment of cancer therapy-lung （FACT-L） and KPS increased 22 and 11 after treatment, there were all significant difference （P〈0.05）. The main toxicities were neutropenia, hemoglobin , and fatigue with mainly grade 1~2.Conclusion Less dose three weeks taxotere was considered as an appropriate treatment for elderly patients with advanced NSCLC.
出处
《临床合理用药杂志》
2011年第10X期50-51,共2页
Chinese Journal of Clinical Rational Drug Use
